OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

This is from the press summary from todays Express:

SHARE WHISPER: OXFORD BIOMEDICA (talk of a potential partnership deal with Johnson & Johnson, which could be mulling a takeover)

Also just listened to the webcast and all that talk of studies takes me back to my uni days. The main subjects covered were the various products they are developing. The work they are doing does sound impressive to me and seems to be coming along nicely. Not sure how this should affect the share price but everything appears to be ticking along nicely.

Thanks nice research - reckon we are bound for "Route 66"

the webcast will be on their site for the next month or so if anyone wants to have a listen. the speech was about half an hour long.

Thanks tbrooking66

How nice OXB UP yet again!

I seem to have timed it right again, on Monday.

Results on Mon 21st March - Licence announcement to coincide would be nice and IMHO expected.

lifted from press round-up of today (from the independant):

*Hopes of cancer treatment licensing deal at Oxford Biomedica (LSE: OXB.L - news) .

Thanks tbrooking66

It started to drop so I lightened up my holding a bit.

I think we may have peaked again for the time being.

Results Monday are unlikely to be great but that may be cancelled out if a licencing deal is announced on the same day.

I've set an automatic stop loss for a chunk of my holding.

Oxford Biomedica PLC
21 March 2005


FOR IMMEDIATE RELEASE 21 MARCH 2005




OXFORD BIOMEDICA PLC

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2004


Oxford, UK - 21 March 2005: Oxford BioMedica (LSE: OXB), the leading gene
therapy company, today announces its preliminary results for the year ended 31
December 2004. Highlights:


Oncology

TroVax: Phase II results in colorectal cancer alongside chemotherapy
exceeded expectations, demonstrating immune responses in all patients and
clinical benefit in the majority. Announced on 2 March 2005

TroVax: Phase I/II follow-up analysis showed a highly significant
correlation between immune responses and time to disease progression

TroVax: Phase II trial in renal cell carcinoma commenced in the United
States

TroVax: commercial manufacture established with over 22,000 doses
produced

TroVax: plans for registration trials to be discussed with the FDA
imminently

Anti-5T4 targeted antibody: Wyeth completed its preclinical evaluation
and clinical trials are under consideration

MetXia: Phase I rolling to Phase II trial in pancreatic cancer underway



Neurotherapy

ProSavin: preclinical results showed almost complete recovery in movement
behaviour in Parkinson's disease

ProSavin: regulatory discussions ongoing prior to formal submissions for
clinical trials

MoNuDin: preclinical results demonstrated a highly significant increase
in life expectancy in ALS, published in Nature

SMN-1G: preclinical results showed a statistically significant
improvement in survival in spinal muscular atrophy, published in the
Journal of Clinical Investigation

Innurex: preclinical results showed restoration of limb function in
avulsion or stretch injury



Technology licensing

Four technology licensing agreements signed during 2004 and another since
the year end, generating sustainable revenue

Merck & Co and Biogen Idec licensed the LentiVector technology for
research use

Viragen licensed the LentiVector technology for biomanufacturing using
avian transgenics

MolMed licensed the retroviral ex vivo gene delivery technology for
therapeutic applications



Financial

Revenue for the year ended 31 December 2004 increased 34 per cent to 0.5
million (2003: 0.4 million) reflecting growing income from licensing

Loss before tax and exceptional items for the year reduced to 11.1
million (2003: 12.7 million)

Operating expenses for the year were essentially unchanged at 13.5
million (2003: 13.7 million)

Cash and short term investments at 31 December 2004 of 22.4 million
(2003: 31.8 million)

Cash resources sufficient to support development activities into 2007,
before taking account of new licensing agreements



Board appointment

Nick Woolf, Senior Vice President for Corporate Strategy, appointed to
the Board as an executive director on 3 March 2005


Commenting on the results, Oxford BioMedica's Chief executive, Professor Alan
Kingsman said: 'We have made good progress during 2004 in both product
development and licensing. In particular, the recent successful Phase II results
with TroVax have confirmed the potential for our lead product. The value of our
technology platforms is also becoming evident. In 2004 and since the year end,
we have secured five technology licensing deals, which are generating growing
and sustainable revenue. More deals on technology and products are expected. At
the same time, we are moving TroVax towards registration trials and taking the
lead neurotherapy products towards clinical development. With our solid cash
position, we are well placed to deliver on our objectives. We look forward to
the coming year as our products and technologies advance towards
commercialisation.'


-Ends-

Looks like I got it right again on Friday.

I wonder how long it will be before the next announcement pushes it up again.

THE INDEPENDENT (online Edition)

22 March 2005


Oxford BioMedica has further hurdles to cross

Ten years ago this month, Oxford BioMedica was created to commercialise some of the biotechnological know-how of Oxford University. Now a quoted company, it has been methodically progressing work on an exciting vaccine that causes a tumour-attacking response by the immune systems of people suffering cancers including of the colon. It has tested this product, TroVax, on 70 people and the company argues it is as close to completely safe as a drug can get. Better still, recent trial results showed it extended patients' lives.

Too good to be true? Possibly not, since OXB has a great scientific track record, with no trial failures to date. But a larger and more expensive trial will have to be conducted before TroVax could be considered for approval, and the UK biotech industry's specialist investors will await the appointment of a bigger company as co-funder and development partner before getting carried away. Private investors should do the same.

There are still many significant hurdles to be overcome before TroVax, or OXB's other self-funded cancer drug, MetXia, can be commercialised. With the shares puffed up thanks to recent abortive merger talks, it is not the time to buy in

The above article is not intended to deramp the sp and I shall still hold. If sp drops to 18p IMHO a good opportunity to top up.

Do you not think (as I sometimes do) that some journalists and even so called experts might purposely "de puff" a share in order to "fill their boots"

Some do. I never trust the journalists anymore. Not since I lost heavily in the past with a morning paper. Two journalists were sacked but unfortunately the owner of the paper got let off

Thanks for the info Barry.

BAD NEWS....THE DIRECTORS ARE SELLING! I think it will go down to 14p. Not looking good.


Oxford Biomedica PLC
22 March 2005


Oxford BioMedica plc ('the Company')

Directors' Interest in Shares and Share Options

Oxford BioMedica (OXB:L) The Company today announced that Peter Nolan and Andrew
Wood, both directors of the Company, had exercised options over 227,731 and
262,346 1p ordinary shares respectively. The exercise price was 15p per share.
The options have been exercised now because they were granted on 7 April 1998,
and if not exercised, would otherwise lapse on 7 April 2005. The option shares
are subject to a block listing, so are already listed. Including the shares
allotted on exercise of these options, the total number of the Company's issued
shares is now 374,019,466. Peter Nolan and Andrew Wood have both sold today all
the shares allotted on the exercise of these options at 19 pence per share.

The total interests of Peter Nolan and Andrew Wood in the Company's 1p ordinary
shares and share options following these transactions are:

Shares Share options
-------------------------- --------- -------

Peter Nolan 87,780 883,498
Andrew Wood 128,950 1,242,750

Andrew Wood
Company Secretary, Oxford BioMedica plc
22 March 2005

Directors selling shares may not be bad news - particularly at this time of year it may well be for tax reasons. IMHO we have interesting times ahead with OXB

Very strong sells again today.

Selling seems popular - my lot are all red !